Recent discussions on X about Amgen (AMGN) have centered around the stock's price movements and technical indicators. Many users have noted the stock's recent decline, with some highlighting a strong ...

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

Why Amgen (AMGN) is on investors’ radar today Amgen (AMGN) is back in focus after recent share price moves, with the stock ...

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (NASDAQ: AMGN) started the year strong, ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen reported progress across its KRAS inhibitor portfolio, including Lumakras and next generation candidates such as AMG 410. The company completed a Phase 3 study for Opdivo biosimilar ABP 206, a ...

Murdo Gordon, EVP at Amgen (NASDAQ:AMGN), executed a substantial insider sell on November 14, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and ...